Janus Henderson Group PLC Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Janus Henderson Group PLC purchased a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 17,700 shares of the biotechnology company’s stock, valued at approximately $159,000.

Several other institutional investors have also recently made changes to their positions in ATXS. KLP Kapitalforvaltning AS acquired a new stake in Astria Therapeutics during the fourth quarter worth $41,000. Tower Research Capital LLC TRC grew its holdings in shares of Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 2,766 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Astria Therapeutics during the 4th quarter worth $50,000. Virtus ETF Advisers LLC acquired a new stake in shares of Astria Therapeutics during the 4th quarter worth about $65,000. Finally, Teacher Retirement System of Texas purchased a new stake in Astria Therapeutics in the 4th quarter valued at about $91,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Down 3.9%

NASDAQ:ATXS opened at $3.92 on Monday. Astria Therapeutics, Inc. has a 52 week low of $3.56 and a 52 week high of $12.92. The company has a fifty day simple moving average of $4.75 and a two-hundred day simple moving average of $7.08. The company has a market cap of $221.22 million, a price-to-earnings ratio of -1.88 and a beta of 0.45.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). On average, analysts expect that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ATXS shares. Wedbush reaffirmed an “outperform” rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. JMP Securities started coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price for the company. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $47.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $30.00.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.